Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections
Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8...
Bayer
Bayer Co.Lab Adds Arbele and Alphelix – China Innovation Cluster Reaches 12 Resident Biotech Startups
Bayer Co.Lab announced that Arbele Limited and Alphelix Bioscience have joined its co-creation platform, bringing...
Bayer Reports EUR 45.6 Billion 2025 Sales – Nubeqa and Kerendia Drive Pharma Growth Amid Xarelto Patent Cliff
Bayer AG (ETR: BAYN) released its 2025 financial results, recording EUR 45.6 billion (USD 52.84 billion) in group...
Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer
Bayer AG (ETR: BAYN) announced that the National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide)...
Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery
Bayer AG (ETR: BAYN) and Vanderbilt University Medical Center (VUMC) announced a strategic five‑year collaboration to...
Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation
Bayer AG (ETR: BAYN) announced an agreement with Attralus, Inc. to acquire two investigational molecular imaging...
Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC
Bayer AG (VIE: BAYN) announced that cevatertinib (BAY 2927088) has been granted Breakthrough Therapy Designation (BTD)...
Bayer’s HYRNUO Wins FDA Approval for HER2-Mutated Lung Cancer
Bayer AG (ETR: BAYN) announced that sevabertinib (trade name HYRNUO) received U.S. FDA approval for...
Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth
Bayer AG (ETR: BAYN) announced on November 12 2025 that its third‑quarter 2025 (2025Q3) performance matched prior‑year...
Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS
Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval...
Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million
Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA)...
Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor
German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August...
Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing...
Bayer and JD Health Collaborate on Dulcolax-Lactulose to Expand China’s Digestive-Health Market
Bayer (ETR: BAYN) and JD Health (HKG: 6618) have launched Dulcolax-branded lactulose in a pioneering...
Bayer AG’s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction ≥40%
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from...
Bayer’s Elinzanetant Granted UK Marketing Authorization for Menopause-Related Vasomotor Symptoms
Germany’s Bayer (ETR: BAYN) this week announced that the UK Medicines and Healthcare products Regulatory...
Bayer and Tsinghua University Renew Strategic Research Pact for Drug Innovation
German pharmaceutical giant Bayer AG (ETR: BAYN) and Tsinghua University announced the signing of their...
Bayer’s Nubeqa Receives Positive CHMP Opinion for mHSPC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced last week that the European Medicines Agency...
ADVANZ PHARMA Acquires Bayer’s Testoviron Commercial Rights in Key Markets
UK-based ADVANZ PHARMA announced the acquisition of commercial rights to testoviron from German giant Bayer...
Bayer Wins Beijing MPA Approval for MEDRAD Stellant D-CE Medical Device
German giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the...